• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • VEGF Inhibitor
    1 Drug classified under this drug class

    All the Drug Class Drugs

    partial basket chart

    Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg/ml.
    VIALS: 1 x 100 mg/4 ml; 1 x 400
    Dosage adjust. individ. for each pt.
    accord to the med. cond. accord. to
    prescr. info.
    Tmt. metastat. Carcinoma of the colon or
    rectum, to be used in combinat. With
    fluoropyrimidine-based chemother.
    Firstline tmt. metastat. Breast cancer, in
    comb. with Paclitaxel. tmt.
    unresect.,advanced, metastat./recurrent
    NSCLC other than predom. squamous cell
    histology, in add. to platinum-based
    chemother. tmt. advanc./metastat. Renal
    cell cancer, in comb. with interferon alfa-
    2a. Firstline tmt. advanc./metastat. Renal
    cell cancer, in comb. with interferon alfa-
    2a. As single agent tmt. glioblastom. In
    pts. with progress. dis. foll. prior ther.
    Front-line tmt. in comb. with paclitaxel.
    and carboplatin advanc. (FIGO III B, III
    C,IV) epithelial ovar., fallop. tube, or
    primary peritoneal canc. in pts at high risk
    for recurrence (resid. dis. aft.debulk.). in
    comb. with carboplatin and gemcitabine
    tmt of adult pts. with first recur.of
    platinum-sensit. epithelial ovar., fallopian
    tube or prim. peritoneal cancer who have
    not received prior therapy with
    Bevacizumab or other VEGF inhibit. or
    VEGF receptor–targeted agents.
    C/I: Hypersens. active substance/
    excips./ chinese hamster ovary/ other recombinant human or humanized
    antibodies., pregn.